Zacks Investment Research
16 Apr 2026, 15:26 UTC · 29w ago
Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy
Impact · against what's priced in
The assignment of a permanent J-code for Epioxa provides a concrete catalyst for Glaukos by streamlining reimbursement and improving physician adoption. This is expected to support a more scalable growth trajectory for the product starting July 1, 2026.
- GKOS+0.40
No priced-in read yet
- In context
The assignment of permanent HCPCS J-code J2789 for Epioxa, effective July 1, 2026, removes a significant billing hurdle and simplifies reimbursement, which is a key driver for scaling adoption and revenue.
Read from the article alone
